Raymond James & Associates Exact Sciences Corp Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Exact Sciences Corp stock. As of the latest transaction made, Raymond James & Associates holds 56,607 shares of EXAS stock, worth $3.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,607
Previous 60,125 5.85%
Holding current value
$3.01 Million
Previous $2.54 Million 51.73%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
SELL
$42.43 - $70.83 $149,268 - $249,179
-3,518 Reduced 5.85%
56,607 $3.85 Million
Q2 2024

Jul 19, 2024
SELL
$41.33 - $74.26 $199,995 - $359,344
-4,839 Reduced 7.45%
60,125 $2.54 Million
Q1 2024

Apr 22, 2024
BUY
$56.27 - $73.77 $114,734 - $150,417
2,039 Added 3.24%
64,964 $4.49 Million
Q4 2023

Jan 16, 2024
BUY
$59.06 - $75.72 $202,575 - $259,719
3,430 Added 5.77%
62,925 $4.66 Million
Q3 2023

Oct 24, 2023
BUY
$65.94 - $99.04 $160,563 - $241,162
2,435 Added 4.27%
59,495 $4.06 Million
Q2 2023

Jul 25, 2023
SELL
$62.68 - $95.05 $105,929 - $160,634
-1,690 Reduced 2.88%
57,060 $5.36 Million
Q1 2023

Apr 14, 2023
SELL
$47.19 - $70.77 $693,881 - $1.04 Million
-14,704 Reduced 20.02%
58,750 $3.98 Million
Q4 2022

Feb 08, 2023
BUY
$30.35 - $53.15 $1,699 - $2,976
56 Added 0.08%
73,454 $3.64 Million
Q3 2022

Oct 25, 2022
SELL
$31.97 - $49.37 $362,955 - $560,497
-11,353 Reduced 13.4%
73,398 $2.39 Million
Q2 2022

Aug 12, 2022
SELL
$35.61 - $76.23 $41,022 - $87,816
-1,152 Reduced 1.34%
84,751 $3.34 Million
Q1 2022

May 11, 2022
BUY
$57.56 - $82.54 $351,231 - $503,659
6,102 Added 7.65%
85,903 $6.01 Million
Q4 2021

Feb 08, 2022
BUY
$72.5 - $100.68 $49,300 - $68,462
680 Added 0.86%
79,801 $6.21 Million
Q3 2021

Nov 02, 2021
BUY
$90.24 - $124.05 $1.27 Million - $1.74 Million
14,033 Added 21.56%
79,121 $7.55 Million
Q2 2021

Aug 11, 2021
BUY
$93.66 - $139.27 $635,670 - $945,225
6,787 Added 11.64%
65,088 $8.09 Million
Q1 2021

May 14, 2021
SELL
$116.57 - $155.01 $1.44 Million - $1.92 Million
-12,392 Reduced 17.53%
58,301 $7.68 Million
Q4 2020

Feb 12, 2021
BUY
$99.61 - $142.12 $1.51 Million - $2.16 Million
15,204 Added 27.4%
70,693 $9.37 Million
Q3 2020

Nov 04, 2020
BUY
$72.92 - $102.01 $25,303 - $35,397
347 Added 0.63%
55,489 $5.66 Million
Q2 2020

Jul 28, 2020
SELL
$55.75 - $92.75 $913,854 - $1.52 Million
-16,392 Reduced 22.91%
55,142 $4.79 Million
Q1 2020

Apr 21, 2020
SELL
$37.9 - $104.44 $940,981 - $2.59 Million
-24,828 Reduced 25.77%
71,534 $4.15 Million
Q4 2019

Feb 12, 2020
BUY
$77.66 - $99.74 $263,578 - $338,517
3,394 Added 3.65%
96,362 $8.91 Million
Q3 2019

Nov 07, 2019
BUY
$90.37 - $122.49 $2.39 Million - $3.24 Million
26,423 Added 39.71%
92,968 $8.4 Million
Q2 2019

Aug 06, 2019
BUY
$89.51 - $118.04 $171,769 - $226,518
1,919 Added 2.97%
66,545 $7.86 Million
Q1 2019

May 06, 2019
BUY
$61.98 - $96.5 $265,522 - $413,406
4,284 Added 7.1%
64,626 $5.6 Million
Q4 2018

Feb 11, 2019
SELL
$56.04 - $82.66 $175,517 - $258,891
-3,132 Reduced 4.93%
60,342 $3.81 Million
Q3 2018

Nov 14, 2018
SELL
$48.29 - $80.6 $747,094 - $1.25 Million
-15,471 Reduced 19.6%
63,474 $5.01 Million
Q2 2018

Aug 14, 2018
SELL
$37.84 - $69.96 $432,057 - $798,803
-11,418 Reduced 12.64%
78,945 $4.72 Million
Q1 2018

May 14, 2018
SELL
$39.82 - $57.53 $335,045 - $484,057
-8,414 Reduced 8.52%
90,363 $3.64 Million
Q4 2017

Feb 14, 2018
BUY
$46.49 - $60.51 $54,300 - $70,675
1,168 Added 1.2%
98,777 $5.19 Million
Q3 2017

Nov 13, 2017
BUY
$37.05 - $47.12 $205,145 - $260,903
5,537 Added 6.01%
97,609 $4.6 Million
Q2 2017

Aug 14, 2017
BUY
N/A
92,072
92,072 $3.26 Million

Others Institutions Holding EXAS

# of Institutions
651
Shares Held
166M
Call Options Held
1.96M
Put Options Held
1.41M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.42B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email